Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’.
GUARD Symposium 2025 Ipi/nivo is less good at getting initial control but has less long-term toxicity.”
More posts featuring Tom Powles on OncoDaily.